NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
Buyers
Value
£580,156,000
Suppliers
- Zentiva Pharma UK Ltd
- GLAXOSMITHKLINE UK LIMITED
- Celltrion Healthcare United Kingdom Limited
- Biogen
- Kent Pharma Ltd
- Amgen Ltd
- Merck Sharpe & Dohme (UK) Limited
- ACCORD-UK LTD
- Neon Healthcare Ltd
- Dr.Reddy's Laboratories (UK) Limited
- Pfizer Ltd
- Bayer plc
- Sandoz Ltd
- Aventis Pharma ltd t/a Sanofi
- Vifor Pharma UK Ltd
- Chugai Pharma UK Ltd
- Sun Pharma UK Ltd
- Sobi (Swedish Orphan Biovitrum Ltd)
- Mylan
- Galapagos Biotech Ltd
- ABBVIE LTD
- Thornton and Ross Ltd
- Merck Serono Limited
- AstraZeneca
- Janssen-Cilag Ltd
- Eli Lilly & Company Ltd
- Roche Products Ltd
- Ipsen
- Organon Pharmaceuticals UK Ltd
- Almirall
- Merz
- Napp Pharmaceuticals Ltd
- CST Pharma Limited
- Pharmacosmos UK Ltd
- Orifarm UK
- Teva UK Limited
- Novo Nordisk
- Novartis Pharmaceuticals UK Ltd
- Gedeon Richter UK Ltd
Classifications
- Pharmaceutical products
Tags
- award
Submission Deadline
1 year ago
Published
8 months ago
Description
Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months
Similar Contracts
AI Bid Assistant
Our AI-powered tool to help you create winning bids is coming soon!
Timeline complete
Complete